Kiyatec Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Later Stage VC
- Investors
-
21
Kiyatec General Information
Description
Developer of patient-specific three-dimensional cell culture testing services designed to predict therapeutic response for cancer treatment selection. The company's testing technology evaluates individual patients' tumour responses ex vivo, enabling oncologists to identify effective therapies and avoid likely non-responders before treatment begins.
Contact Information
Website
www.kiyatec.comCorporate Office
- 2 North Main Street
- Greenville, SC 29601
- United States
Corporate Office
- 2 North Main Street
- Greenville, SC 29601
- United States
Kiyatec Timeline
Kiyatec Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Later Stage VC | 14-Nov-2025 | Completed | Generating Revenue | |||
| 14. Mezzanine | 06-Nov-2024 | Completed | Generating Revenue | |||
| 13. Later Stage VC (Series C) | 18-May-2023 | Completed | Generating Revenue | |||
| 12. Later Stage VC (Series C1) | 30-Apr-2021 | Completed | Generating Revenue | |||
| 11. Debt - PPP | 30-Apr-2020 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series B3) | 08-Jan-2020 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series B2) | 01-May-2019 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 27-Nov-2017 | Cancelled | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 27-Jan-2017 | $3.15M | $6.8M | Completed | Generating Revenue | |
| 6. Later Stage VC | 04-Nov-2013 | $250K | $3.65M | Completed | Generating Revenue |
Kiyatec Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series C1 | ||||||||
| Series B2 | ||||||||
| Series B | 171,640 | $0.001000 | 8% | $23.32 | $23.32 | 1x | $23.32 | 8.6% |
| Series A | 158,320 | $0.001000 | 8% | $17.5 | $17.5 | 1x | $17.5 | 7.93% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Kiyatec Comparisons
Industry
Financing
Details
Kiyatec Competitors (27)
One of Kiyatec’s 27 competitors is Coave Therapeutics, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Coave Therapeutics | Venture Capital-Backed | Paris, France | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| WindMIL Therapeutics | Venture Capital-Backed | Baltimore, MD | ||||
| Adverum Biotechnologies | Formerly VC-backed | Redwood City, CA | ||||
| Verge Labs | Venture Capital-Backed | San Francisco, CA |
Kiyatec Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kiyatec Patents
Kiyatec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3159387-A1 | Methods of screening to determine effective dosing of cancer therapeutics | Pending | 08-Nov-2019 | ||
| EP-4055384-A2 | Methods of screening to determine effective dosing of cancer therapeutics | Inactive | 08-Nov-2019 | ||
| US-20230042929-A1 | Methods of screening to determine effective dosing of cancer therapeutics | Inactive | 08-Nov-2019 | ||
| WO-2021092555-A2 | Methods of screening to determine effective dosing of cancer therapeutics | Inactive | 08-Nov-2019 | ||
| WO-2021092555-A3 | Methods of screening to determine effective dosing of cancer therapeutics | Inactive | 08-Nov-2019 | G01N33/575 |
Kiyatec Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kiyatec Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Medical & Bio Decision | VC-Backed Company | Minority | ||
| Bruker | Corporation | Minority | ||
| The Brain Tumor Investment Fund | Not-For-Profit Venture Capital | Minority | ||
| The Sontag Foundation | Limited Partner | Minority | ||
| Angel (individual) | Minority |
Kiyatec FAQs
-
When was Kiyatec founded?
Kiyatec was founded in 2005.
-
Where is Kiyatec headquartered?
Kiyatec is headquartered in Greenville, SC.
-
What is the size of Kiyatec?
Kiyatec has 15 total employees.
-
What industry is Kiyatec in?
Kiyatec’s primary industry is Medical Supplies.
-
Is Kiyatec a private or public company?
Kiyatec is a Private company.
-
What is Kiyatec’s current revenue?
The current revenue for Kiyatec is .
-
How much funding has Kiyatec raised over time?
Kiyatec has raised $32.9M.
-
Who are Kiyatec’s investors?
Medical & Bio Decision, Bruker, The Brain Tumor Investment Fund, The Sontag Foundation, and are 5 of 21 investors who have invested in Kiyatec.
-
Who are Kiyatec’s competitors?
Coave Therapeutics, Renova Therapeutics, WindMIL Therapeutics, Adverum Biotechnologies, and Verge Labs are some of the 27 competitors of Kiyatec.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
